Only patients with AML develop NuSAP1 Ab and CHAF1b Ab after HCT. (A-B) NuSAP1 and CHAF1b are predominant in patients with AML compared with other diseases/leukemia as identified by quantitative IgG ELISA. OD readings that tested positive were higher than the mean of 70 healthy persons plus 3 SDs (solid line across the graphs).